CMC Biologics Recognized for Quality and Reliability at the 2015 CMO Leadership Awards Ceremony
SEATTLE and BERKELEY, California and COPENHAGEN, Denmark, March 19, 2015 /PRNewswire/ -- CMC Biologics, Inc., a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein-based therapeutics, was recognized for the third consecutive year for quality and reliability by Life Science Leader at an awards ceremony at DCAT Week '15 in New York.
Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO
"The CMC Biologics' team is honored to receive this prestigious award as recognition from our customers and the industry as a whole," said Gustavo Mahler, PhD, Global Chief Operations Officer. "Our customers count on us to deliver comprehensive process development and manufacturing solutions essential for their clinical and commercial success; and this award underscores our proven track-record in technical excellence and customer satisfaction across every aspect of our business."
Bringing new pharmaceutical products to market is time consuming and costly, thereby having reliable and effective contract organizations to work with helps streamline that process. The Life Science Leader CMO Leadership awards are designed to honor top performers based on survey responses from thousands of industry executives, conducted by Nice Insight, and to better serve biopharmaceutical executives in their CMO selection process. This data will help companies focus on potential CMO partners who can manage their projects and are considered most reputable in the industry.
About CMC Biologics
CMC Biologics is leading the industry among CMO's in reliability, technical excellence, and quality – Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scaleup and cGMP manufacture of protein- based therapeutics for preclinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.
More detailed information can be found at www.cmcbiologics.com.
Share this article